The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer

• Published in: BioMed research international Vol. 2020; no. 2020; pp. 1 - 15
• Main Authors: Zheng, Jingyu, Xia, Weiting, Chen, Wenming, Zheng, Ruoyi, Zhou, Qing
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2020; Hindawi; Hindawi Limited
• Subjects: Apoptosis; Cancer; Cell growth; Chemotherapy; Databases, Genetic; Datasets; Female; Gene expression; Gene Expression Regulation, Neoplastic; Growth factors; Histology; Humans; Insulin; Insulin-Like Growth Factor Binding Proteins - genetics; Insulin-Like Growth Factor Binding Proteins - metabolism; Insulin-like growth factor-binding protein 1; Insulin-like growth factor-binding protein 2; Insulin-like growth factor-binding protein 4; Insulin-like growth factor-binding protein 5; Insulin-like growth factor-binding protein 6; Insulin-like growth factors; Medical prognosis; Ovarian cancer; Ovarian Neoplasms - genetics; Prognosis; Proteins; RNA, Messenger - genetics; RNA, Messenger - metabolism; Survival; Survival Analysis; Tumor markers
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2020/7658782

Purpose. To assess the expression of insulin-like growth factor binding protein (IGFBP) family and its prognostic impact in ovarian cancer (OC) patients. Materials and Methods. The mRNA expression and protein expression of individual IGFBPs in healthy ovarian samples and OC tissues were explored through Oncomine, Gene Expression Profiling Interactive Analysis, and Human Protein Atlas database. Additionally, the prognostic values of the six IGFBP members in patients with OC were evaluated by Kaplan-Meier plotter. Results. IGFBP2 and IGFBP4 mRNA expression were remarkably upregulated in patients with OC. To be specific, the mRNA expression of IGFBP2 was upregulated in patients with serous ovarian cancer (SOC), while IGFBP1/3/4/5/6 mRNA levels were downregulated. In addition, the IGFBP4 protein expression was upregulated in SOC, and the IGFBP6 protein expression was upregulated in both of SOC and endometrioid ovarian cancer (EOC) tissues. High IGFBP1 mRNA levels showed favorable overall survival (OS) and progression-free survival (PFS) in all OC. Meanwhile, increased IGFBP5/6 mRNA levels revealed worsen OS and PFS in all OC patients. IGFBP4/6 mRNA levels predicted unfavorable OS and PFS only in SOC patients. Moreover, the aberrant mRNA expression of IGFBP1/2/4/5/6 was correlated with significantly prognosis in patients receiving different chemotherapeutic regimens. Conclusion. This study indicates that the IGFBP family reveals distinct prognosis in patients with OC. IGFBP1/2/4/5/6 are useful prognostic predictors for chemotherapeutic effect in OC patients, and IGFBP2/4 are potential tumor markers for the diagnosis of OC.